Imunon, Inc. annual report, FY2018

Filing scope and business context

Registrant mismatch: The supplied filing is Celsion Corporation’s Form 10-K, not an Imunon, Inc. filing. It covers the fiscal year ended December 31, 2018; it is not a standalone fourth-quarter report. The filing does not provide a clear set of Q4-only financial results.

Celsion was a clinical-stage oncology company with no product sales. Its lead candidate, ThermoDox, was in a Phase III trial (OPTIMA) for primary liver cancer; GEN-1 was in clinical development for ovarian cancer. The company relied on licensing revenue, financing and cash reserves.

Financial performance and liquidity

Revenue was the annual recognition of a previously received Hisun payment, not product sales. The 2018 net loss included a $10.4 million tax benefit from selling New Jersey tax losses. Without that benefit, pretax loss was $22.3 million. Other notable items included a $4.5 million non-cash impairment of the GBM in-process research and development asset and a $3.6 million non-cash gain from reducing the EGEN earn-out liability. Operating expenses exceeded revenue substantially; operating margins are not meaningful for this pre-commercial business.

At year-end, cash, cash equivalents, short-term investments and accrued interest totaled $27.7 million; working capital was $22.0 million. Management expected cash resources to fund operations into the third quarter of 2020. The company reported approximately $31 million of potential equity-sale capacity through Aspire Capital and JonesTrading, but these facilities were not equivalent to cash on hand and the company had no other committed capital sources.

Celsion drew a $10 million Horizon loan in June 2018, reported at $9.4 million net of financing costs at year-end. It bears interest at one-month LIBOR plus 7.625% (effective rate 9.98% at December 31, 2018), is secured by substantially all assets other than intellectual property, and has two years of interest-only payments followed by amortization. Total liabilities were $26.0 million at year-end.

Changes versus 2017

• Net loss narrowed to $11.9 million from $20.4 million, primarily reflecting the New Jersey tax-loss sale benefit; the underlying pretax loss increased to $22.3 million from $20.4 million.
• R&D expense fell by $1.2 million, including lower OPTIMA costs following completion of enrollment. G&A rose by $3.8 million, including higher compensation and $2.3 million of additional non-cash stock-based compensation.
• Operating cash use declined by $9.6 million. Financing included $9.7 million net proceeds from the Horizon loan and $0.9 million net equity proceeds.
• Year-end cash and investments including interest receivable increased to $27.7 million from $24.2 million; the company also added debt and recorded the GBM asset impairment.

Outlook, developments and risks

• OPTIMA enrolled 556 patients in August 2018. Its primary endpoint is overall survival, with interim efficacy analyses expected in the second half of 2019 and mid-2020; final analysis, if needed, was expected in early 2021. In December 2018, the independent data monitoring committee recommended continuing the trial to final readout. This review addressed safety and data integrity and should not be interpreted as a finding of efficacy.
• The earlier Phase III HEAT trial failed its primary progression-free-survival endpoint. The company’s rationale for OPTIMA relied in part on retrospective subgroup analyses from HEAT, which management cautioned should be viewed carefully.
• OVATION 2 began dosing in September 2018. The filing described a planned randomized Phase II comparison of GEN-1 plus chemotherapy against chemotherapy alone. Subsequent to year-end, the company reported OVATION I median progression-free survival of 21 months for 14 per-protocol patients and 17.1 months for the 18-patient intent-to-treat population; this was early-stage, small-study evidence, not confirmatory trial evidence.
• The company expected no product revenue for the foreseeable future and stated that additional funding would be required to continue development. Equity financing could dilute shareholders; failure to obtain funding could delay, reduce or terminate programs.
• Key risks include clinical and regulatory failure, the prior HEAT primary-endpoint miss, reliance on third-party trial operators and manufacturers, competition, intellectual-property and licensing exposure, and uncertainty about reimbursement and commercialization. The company had no internal sales or marketing capability.
• After year-end, a March 2019 amendment changed terms for a potential $12.4 million ovarian-cancer earn-out: if the milestone is achieved, Celsion may pay $7.0 million cash within 10 business days or $12.4 million in cash, stock or a combination within one year. The amendment also extended the earn-out term and provided for 200,000 warrants at a $0.01 exercise price.

Important facts for investors to verify

• Confirm the intended issuer: the supplied document identifies Celsion Corporation (NASDAQ: CLSN), not Imunon, Inc.
• Check OPTIMA’s interim and final results, including whether survival benefit is demonstrated; the filing reports enrollment and a continue-as-planned DMC recommendation, not efficacy results.
• Assess cash burn and financing runway against the stated third-quarter 2020 estimate, and distinguish available equity facilities from committed funding and cash on hand.
• Review the Horizon loan’s interest, collateral, covenants and repayment schedule, along with potential dilution from equity facilities and outstanding securities.
• Evaluate the assumptions behind the $10.4 million tax benefit, the GBM impairment and the fair-valued EGEN earn-out liability, including the subsequent ovarian milestone amendment.